In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver
- PMID: 2894945
In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver
Abstract
Competitive inhibition studies using human liver microsomes have shown that quinidine (QD) has an exceptionally high affinity (60 nM) for the genetically variable cytochrome P-450 that catalyzes the formation of 4-hydroxydebrisoquine and dehydrosparteines from debrisoquine and sparteine. The present study examined the effect of sparteine and debrisoquine on the oxidation of QD by microsomes prepared from two human livers. QD and its major metabolite 3-hydroxy-QD were measured by quantitative TLC. QD 3-hydroxylation followed saturable single-site kinetics over a 1-250 microM range of QD concentrations. The Km and Vmax of the reaction in the two liver specimens were 47.5 +/- 3.5 microM and 58.7 +/- 5.9 microM, and 0.36 +/- 0.08 and 0.29 +/- 0.02 nmol of 3-hydroxy-QD/mg of protein/min. Sparteine and debrisoquine (250 microM) had no effect on this QD 3-hydroxylase activity. Furthermore, near-saturation of the sparteine/debrisoquine isozyme by 250 microM sparteine had no effect on the oxidation of QD by all routes (measured by QD disappearance from an initial level of 70 nM during an 8-hr incubation period). These observations indicate that none of the major oxidative reactions of QD are catalyzed by the sparteine/debrisoquine isozyme; QD may simply bind to this cytochrome P-450, without being oxidized by it.
Similar articles
-
Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.Drug Metab Dispos. 1989 May-Jun;17(3):334-40. Drug Metab Dispos. 1989. PMID: 2568917
-
Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.Mol Pharmacol. 1983 Mar;23(2):474-81. Mol Pharmacol. 1983. PMID: 6220203
-
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.J Pharmacol Exp Ther. 1988 Oct;247(1):242-7. J Pharmacol Exp Ther. 1988. PMID: 3171974
-
Polymorphic oxidation of debrisoquine and sparteine.Prog Clin Biol Res. 1986;214:157-67. Prog Clin Biol Res. 1986. PMID: 3523506 Review. No abstract available.
-
The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.Pharmacol Ther. 1990;46(2):297-308. doi: 10.1016/0163-7258(90)90096-k. Pharmacol Ther. 1990. PMID: 2181495 Review.
Cited by
-
Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.Eur J Clin Pharmacol. 1995;48(6):501-4. doi: 10.1007/BF00194341. Eur J Clin Pharmacol. 1995. PMID: 8582470 Clinical Trial.
-
Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.Br J Clin Pharmacol. 1990 Feb;29(2):248-53. doi: 10.1111/j.1365-2125.1990.tb03628.x. Br J Clin Pharmacol. 1990. PMID: 2306418 Free PMC article.
-
A Review on New Frontiers in Drug-Drug Interaction Predictions and Safety Evaluations with In Vitro Cellular Models.Pharmaceutics. 2025 Jun 6;17(6):747. doi: 10.3390/pharmaceutics17060747. Pharmaceutics. 2025. PMID: 40574059 Free PMC article. Review.
-
The inhibition of CYP enzymes in mouse and human liver by pilocarpine.Br J Pharmacol. 1995 Feb;114(4):832-6. doi: 10.1111/j.1476-5381.1995.tb13279.x. Br J Pharmacol. 1995. PMID: 7773543 Free PMC article.
-
New insights into quetiapine metabolism using molecular networking.Sci Rep. 2020 Nov 16;10(1):19921. doi: 10.1038/s41598-020-77106-x. Sci Rep. 2020. PMID: 33199804 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources